FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

Submitted by admin on May 4, 2018 - 9:58am
Source: 
CP Wire
News Tags: 
Akcea
hereditary ATTR amyloidosis
FDA
inotersen
Alnylam
Patisiran
Headline: 
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
snippet: 
The FDA extended the PDUFA goal date of Akcea's hereditary TTR amyloidosis drug inotersen to October 6, 2018. 

Do Not Allow Advertisers to Use My Personal information